Patients now have access to a ground-breaking Advanced Diagnostic Laboratory cancer predictive Test for patients at risk of oral cancer.
Dallas, TX; October 28, 2024 – Proteocyte announced today that United Healthcare (UHC) is providing coverage for Straticyte™ for National, Regional, and Employer Group plans for patients that are commercially-insured, have Medicare Advantage, and/or Managed Medicaid. United Healthcare is the largest managed care organization in the United States and is the first US insurer to reimburse the cost of Proteocyte’s Staticyte™ test. This development will significantly expand access to the Staticyte™ test for patients with Oral Potential Malignant Diseases (OPMD)
“Oral and maxillofacial surgeons, dentists, and periodontists, are excited about the Staticyte™ test because they now have something that can potentially have a huge impact on survival rates”, said Mark Hammar, Proteocyte CEO. “This coverage will mean so much for their patients”, he added.
The Straticyte™ test is a ground-breaking Advanced Diagnostic Laboratory cancer predictive Test (ADLT/MAAA). Healthcare professionals (HCPs) across the U.S. are now able to provide this new innovative management option which predicts whether a suspicious oral lesion may become malignant. When a patient presents with a mouth sore or lesion, on their lips, gums, and/or tongue, HCPs can now quickly determine the 5-year risk of it developing into oral cancer. The StraticyteTM test is easily incorporated into clinical practice with no additional biopsies required. After 40 years with little change in the standard of care for patients with OPMD, patients now have a way to take charge of their health.
“The current standard of care is highly subjective, poorly reproducible and inadequate, contributing to a large number of patients presenting with late-stage disease, limited and expensive treatment options, and low survival rate. Straticyte, with this reimbursement, is an absolute game changer”, declared Dr. Anthony Morlandt, Chief Medical Officer-USA, Head and Neck Surgeon / Oral Oncology, University of Alabama, Birmingham.
About Oral Cancer
Oral lesions (“OPMD” — Oral Potentially Malignant Diseases) are common, with about 2.5% of the U.S. population experiencing these lesions annually with approximately 12,000,000 cases in North America alone. Of these patients, more than 50,000 will be diagnosed with oral cancer, resulting in one oral cancer death every 45 minutes. 70% of those will be diagnosed at late stage with a 50% mortality rate due in part to the current standard of care for assessing OPMD patients.
About Proteocyte
Proteocyte, Inc., is a personalized medicine and diagnostics company located in MaRS Center, Toronto ON. Proteocyte’s products help tackle the uncertainty surrounding oral cancer care, one of the most aggressive human cancers. The company’s oral dysplasia predictive test, Straticyte, was developed from a panel of 811 protein biomarkers, leverages over 10 years of R&D, and is positioned to disrupt oral dysplasia and cancer care worldwide.
For more information, visit: https://proteocyte.com/straticyte/
For further information contact:
Todd Conrad (Media Contact)
Proteocyte AI US, INC.
4514 Cole Ave. Ste 930
Dallas, TX 75205
1-833-577-6836
[email protected]